Tracers / [131I]KN046
[131I]KN046
Also written as [I-131]KN046
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Bispecific single-domain antibody-Fc fusion protein (anti-PD-L1/CTLA-4)
- Target / mechanism
- PD-L1 and CTLA-4 dual targeting PMID 36242616
- Clinical application
- Radioimmunotherapy for malignant melanoma, enhancing antitumor immune response PMID 36242616
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | 99.99% | — | KN046 | 36242616 2023 Eur J Nucl Med Mol Imaging KN046 was labeled with [131I] using the catalyst iodogen. — The initial labeling yield of [131I]-KN046 was 99.99% |
Need this precursor?We can point you to suppliers for [131I]KN046, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36242616. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.